|
|
Vaccine Detail
|
rMV-Ed-G |
| Vaccine Information |
- Vaccine Name: rMV-Ed-G
- Target Pathogen: Nipah virus
- Target Disease: Nipah virus disease
- Vaccine Ontology ID: VO_0004714
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- G glycoprotein
gene engineering:
- Type: Recombinant vector construction
- Description: A recombinant measles virus (rMV) vaccine expressing NiV envelope glycoproteins (rMV-HL-G and rMV-Ed-G) (Yoneda et al., 2013).
- Detailed Gene Information: Click Here.
- Vector:
- Preparation: Recombinant measles virus (rMV) vaccine expressing NiV envelope glycoproteins (rMV-HL-G and rMV-Ed-G) (Yoneda et al., 2013).
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Hamster Response
- Vaccination Protocol: 8-week-old golden hamsters were intraperitoneally immunized with 2×10^4 TCID50 of rMV-HL-G or rMV-Ed-G (Yoneda et al., 2013).
- Vaccine Immune Response Type: VO_0003057
- Challenge Protocol: All hamsters were challenged intraperitoneally with 10^3 TCID50/animal of NiV (Yoneda et al., 2013).
- Efficacy: All hamsters vaccinated with rMV-HL-G or rMV-Ed-G showed complete protection. During the observation period (14 days after the challenge), all hamsters immunized with the recombinant MVs showed no clinical symptoms of the disease and survived (Yoneda et al., 2013).
|
| References |
Yoneda et al., 2013: Yoneda M, Georges-Courbot MC, Ikeda F, Ishii M, Nagata N, Jacquot F, Raoul H, Sato H, Kai C. Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge. PloS one. 2013; 8(3); e58414. [PubMed: 23516477].
|
|
